The European Medicines Agency (EMA) has announced that it has published new information on the latest additions to its Covid-19 web page and the precautionary marketing suspension of the thalassaemia medicine Zynteglo.
The Agency’s latest updates also include publication of the AstraZeneca European Public Assessment Report, information on the application for conditional marketing authorisation of the Janssen Covid vaccine that the EMA had received, and the start of the rolling review of CureVac’s Covid-19 vaccine (CVnCoV).
Also, in-mid February, the European Commission hosted a webinar titled ‘Covid-19 vaccination — What you need to know as a health professional’. The presentations shared during this webinar by the Directorate-General for Health and Food Safety, the EMA and the European Centre for Disease Prevention and Control can be accessed and downloaded via the website of DG SANTE.
The presentations can be downloaded at https://ec.europa.eu/health/policies/events/ev_20210210_en.
